Literature DB >> 31508180

THE EFFECT OF ANTITHYROID DRUGS ON OSTEOPONTIN AND OXIDATIVE STRESS IN GRAVES' DISEASE.

M Kocak1, E Akarsu2, H Korkmaz3, S Taysi4.   

Abstract

OBJECTIVE: The aim of the present study is to evaluate the effects of methimazole (MTZ) and propylthiouracil (PTU) treatments on osteopontin (OPN) and oxidative stress in Graves' disease (GD).
MATERIAL AND METHODS: The study included 60 cases with GD in hyperthyroid state and taking no antithyroid treatment, and 30 healthy volunteers. GD patients were randomly separated into two groups; 30 of them took PTU, and the other 30 took MTZ treatments. Blood samples were taken from the patients with GD before the treatment, and three months after the treatment was begun, when they were in the euthyroid state; blood samples of the healthy control subjects were also taken at these times.
RESULTS: TAS and OSI levels before treatment were significantly higher in the GD group, when compared to the control group (p<0.001, for each). GD subjects taking PTU treatment had significantly higher TAS levels (p=0.001), and significantly lower TOS and OSI levels (p=0.008 and p=0.001, respectively). TAS levels significantly decreased in the patients taking MTZ treatment (p=0.029), but TOS and OSI levels did not change significantly (p>0.05). Pretreatment OPN levels were significantly higher in GD patients, when compared to the control group (p=0.014). OPN level significantly decreased in the GD group taking PTU treatment; however OPN levels in the group taking MTZ treatment did not change significantly when compared to the pretreatment value.
CONCLUSION: PTU treatment is more effective in decreasing OPN and oxidative stress in GD patients, when compared to the MTZ treatment.

Entities:  

Keywords:  Graves’ disease; methimazole; osteopontin; oxidative stress; propylthiouracil

Year:  2019        PMID: 31508180      PMCID: PMC6711651          DOI: 10.4183/aeb.2019.221

Source DB:  PubMed          Journal:  Acta Endocrinol (Buchar)        ISSN: 1841-0987            Impact factor:   0.877


  25 in total

1.  Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity.

Authors:  S Ashkar; G F Weber; V Panoutsakopoulou; M E Sanchirico; M Jansson; S Zawaideh; S R Rittling; D T Denhardt; M J Glimcher; H Cantor
Journal:  Science       Date:  2000-02-04       Impact factor: 47.728

Review 2.  Antithyroid drugs.

Authors:  David S Cooper
Journal:  N Engl J Med       Date:  2005-03-03       Impact factor: 91.245

3.  A new automated colorimetric method for measuring total oxidant status.

Authors:  Ozcan Erel
Journal:  Clin Biochem       Date:  2005-10-07       Impact factor: 3.281

4.  Determination of oxidative stress in thyroid tissue and plasma of patients with Graves' disease.

Authors:  Evin Ademoğlu; Neşe Ozbey; Yeşim Erbil; Sevda Tanrikulu; Umut Barbaros; Burcu Tulumoğlu Yanik; Alp Bozbora; Selçuk Ozarmağan
Journal:  Eur J Intern Med       Date:  2006-12       Impact factor: 4.487

Review 5.  Osteopontin; as a target molecule for the treatment of inflammatory diseases.

Authors:  Junko Morimoto; Shigeyuki Kon; Yutaka Matsui; Toshimitsu Uede
Journal:  Curr Drug Targets       Date:  2010-04       Impact factor: 3.465

6.  Increased oxidative stress in infants exposed to passive smoking.

Authors:  Ali Aycicek; Ozcan Erel; Abdurrahim Kocyigit
Journal:  Eur J Pediatr       Date:  2005-07-16       Impact factor: 3.183

7.  A novel automated method to measure total antioxidant response against potent free radical reactions.

Authors:  Ozcan Erel
Journal:  Clin Biochem       Date:  2004-02       Impact factor: 3.281

8.  Oxidative stress: a required condition for thyroid cell proliferation.

Authors:  Sylvie Poncin; Sandrine Van Eeckoudt; Kevin Humblet; Ides M Colin; Anne-Catherine Gérard
Journal:  Am J Pathol       Date:  2010-01-21       Impact factor: 4.307

9.  Plasma lipid hydroperoxides measurement by an automated xylenol orange method.

Authors:  Khelifa Arab; Jean-Paul Steghens
Journal:  Anal Biochem       Date:  2004-02-01       Impact factor: 3.365

Review 10.  Osteopontin: a multifunctional protein at the crossroads of inflammation, atherosclerosis, and vascular calcification.

Authors:  Hyun-Ju Cho; Hyun-Jai Cho; Hyo-Soo Kim
Journal:  Curr Atheroscler Rep       Date:  2009-05       Impact factor: 5.113

View more
  2 in total

Review 1.  Relationship between Osteopontin and Bone Mineral Density.

Authors:  A Vancea; O Serban; D Fodor
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Oct-Dec       Impact factor: 1.104

2.  Parameters of Oxidative Stress, Vitamin D, Osteopontin, and Melatonin in Patients with Lip, Oral Cavity, and Pharyngeal Cancer.

Authors:  Jarosław Nuszkiewicz; Jolanta Czuczejko; Marta Maruszak; Marta Pawłowska; Alina Woźniak; Bogdan Małkowski; Karolina Szewczyk-Golec
Journal:  Oxid Med Cell Longev       Date:  2021-10-20       Impact factor: 6.543

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.